Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers
*HMBD-001, a differentiated anti-HER3 monoclonal antibody discovered and developed with Hummingbird Bioscience's AI Molecular Medicine (AIMM) platform, has advanced into Phase II clinical development*Recommended doses for expansion (RDEs) iden
